For beverage companies, this means GLP-1s are no longer a fringe topic but have become a meaningful influence on how consumers think about appetite, weight management, satiety and metabolic health, he says
Liraglutide and renal outcomes in type 2 diabetes: results of the LEADER trial
Join the discussion at the 6th International Keto Live Conference from June 8th to 12th at the Hotel Reine Victoria in St
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist
Early Discoveries, With More to Come So far, GLP-1s, first approved 20 years ago for type 2 diabetes and later obesity, have shown potential in treating a surprisingly wide range of conditions, such as heart disease, Parkinsons, Alzheimers, sleep apnea, and liver disease